Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
Patients coinfected with HIV, HCV showed spontaneous HCV clearance during ART

Three patients coinfected with hepatitis C virus and HIV spontaneously became negative for HCV RNA while undergoing antiretroviral therapy, and all had the IL28B CC genotype in a recent study.

Published
07 July 2014
From
Healio
Bristol-Myers Squibb Receives Positive CHMP Opinion for Daklinza® (daclatasvir) for Treatment of Chronic Hepatitis C in the European Union

Bristol-Myers Squibb Company (NYSE:BMY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending that Daklinza® (daclatasvir), an investigational, potent pan-genotypic NS5A complex inhibitor (in vitro), be granted approval for use in combination with other medicinal products for the treatment of chronic hepatitis C virus (HCV) infection in adults.

Published
30 June 2014
From
Bristol-Myers Squibb press release
Fighting for their lives: Economist Intelligence Unit report finds patient groups lead global efforts to address hepatitis C

New report calls on governments to play their part and improve surveillance, screening and diagnosis of hepatitis C worldwide.

Published
25 June 2014
From
Janssen press release
HCV drug out of the running

The German pharmaceutical giant Boehringer Ingelheim is stopping development of faldaprevir, its hepatitis C virus (HCV) drug.

Published
23 June 2014
From
MedPage Today
A 4-week hep C cure? Bristol to test drugs with Gilead's Sovaldi

In the race to find a faster cure for hepatitis C, Bristol-Myers Squibb Co said it will test its experimental antiviral drug combination with Gilead Sciences Inc's blockbuster drug Sovaldi, hoping to cut treatment time to four weeks.

Published
23 June 2014
From
Reuters
HCV is a major reason for healthcare utilisation in the United States

Patients with hepatitis C virus (HCV) infection are significant users of healthcare services in the United States, according to research published in the online edition of Clinical

Published
23 June 2014
By
Michael Carter
2014 UK Consensus Guidelines — Hepatitis C Management and Direct-acting Anti-viral Therapy

These expert guidelines are sponsored by the Scottish government and take representative opinion from the British Society of Gastroenterology Liver Committee, British Association for the Study of Liver, the Scottish Society of Gastroenterology, the Scottish Viral Hepatitis group, the Scottish Viral Hepatitis Nurses group and the British Viral Hepatitis group.

Published
19 June 2014
From
Medscape (requires registration)
UNITED STATES: FDA Approves AbbVie's Hepatitis C Regimen for Priority Review

The US Food and Drug Administration (FDA) has granted priority review for AbbVie’s experimental all-oral regimen for treating adults infected with hepatitis C virus (HCV). The drug’s application under priority review means that FDA must evaluate the safety and effectiveness of the AbbVie regimen within six months before letting the manufacturer know whether they may take the product to market. AbbVie’s new regimen consists of an antiviral called ritonavir and a protease inhibitor called ABT-450, combined with an NS5A inhibitor called ombitasvir and the polymerase inhibitor dasabuvir. When taken together, these mechanisms are powerful enough to stop HCV. [Article source: http://www.techtimes.com]

Published
19 June 2014
From
CDC
AbbVie all-oral hepatitis C therapy gets rapid EU review

The U.S. drugmaker said on Tuesday the move by the European Medicines Agency meant that, if approved, its regimen could be available in the European Union in the first quarter of 2015. U.S. regulators have also granted the product priority review.

Published
17 June 2014
From
Reuters
NICE rejection looms for Sovaldi

In a draft recommendation published today NICE is asking Gilead for more information on its new hepatitis C pill Sovaldi (sofosbuvir) – and is currently not minded to recommend the treatment for NHS England funding.

Published
16 June 2014
From
Pharmafile

Filter by country